SREBP-2, a new target of metformin?

@inproceedings{Zhang2018SREBP2AN,
  title={SREBP-2, a new target of metformin?},
  author={Fengxia Zhang and Wenxiu Sun and Jianbo Chen and Lusheng Jiang and Ping Yang and Yufang Huang and Aihua Gong and Shudong Liu and Shizhan Ma},
  booktitle={Drug design, development and therapy},
  year={2018}
}
Background Metformin, as the first-line treatment anti-diabetic drug, represents increasing evidence of a potential efficacy in improving dyslipidemia. However, the exact molecular mechanism(s) by which metformin influences lipid metabolism remains incompletely understood. Methods The HepG2 cells were treated with metformin and the AMP-activated protein kinase (AMPK) inhibitor compound C or a dominant-negative form of AMPK plasmid. ELISA assay was employed to measure AMPK activity, and… CONTINUE READING